TrialESMO open2025

Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial.

M Bartoletti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.